{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:35:50Z","timestamp":1789079750469,"version":"build-2803163510"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01CA137008-08"],"award-info":[{"award-number":["5R01CA137008-08"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Postprogression repeat biopsies are critical in caring for patients with lung cancer with epidermal growth factor receptor (EGFR) mutations. However, hesitation about invasive procedures persists. We assessed safety and tissue adequacy for molecular profiling among repeat postprogression percutaneous transthoracic needle aspirations and biopsies (rebiopsies).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>All lung biopsies performed at our hospital from 2009 to 2017 were reviewed. Complications were classified by Society of Interventional Radiology criteria. Complication rates between rebiopsies in EGFR-mutants and all other lung biopsies (controls) were compared using Fisher's exact test. Success of molecular profiling was recorded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During the study period, nine thoracic radiologists performed 107 rebiopsies in 75 EGFR-mutant patients and 2,635 lung biopsies in 2,347 patients for other indications. All biopsies were performed with computed tomography guidance, coaxial technique, and rapid on-site pathologic evaluation (ROSE). The default procedure was to take 22-gauge fine-needle aspirates (FNA) followed by 20-gauge tissue cores. Minor complications occurred in 9 (8.4%) rebiopsies and 503 (19.1%; p = .004) controls, including pneumothoraces not requiring chest tube placement (4 [3.7%] vs. 426 [16.2%] in rebiopsies and controls, respectively; p &amp;lt; .001). The only major complication was pneumothorax requiring chest tube placement, occurring in zero rebiopsies and 38 (1.4%; p = .4) controls. Molecular profiling was requested in 96 (90%) rebiopsies and successful in 92\/96 (96%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>At our center, repeat lung biopsies for postprogression molecular profiling of EGFR-mutant lung cancers result in fewer complications than typical lung biopsies. Coaxial technique, FNA, ROSE, and multiple 20-gauge tissue cores result in excellent specimen adequacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Repeat percutaneous transthoracic needle aspirations and biopsies for postprogression molecular profiling of epidermal growth factor receptor (EGFR)-mutant lung cancer are safe in everday clinical practice. Coaxial technique, fine-needle aspirates, rapid on-site pathologic evaluation, and multiple 20-gauge tissue cores result in excellent specimen adequacy. Although liquid biopsies are increasingly used, their sensitivity for analysis of resistant EGFR-mutant lung cancers remains limited. Tissue biopsies remain important in this context, especially because osimertinib is now in the frontline setting and T790M is no longer the major finding of interest on molecular profiling.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0158","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T19:20:13Z","timestamp":1559330413000},"page":"1570-1576","source":"Crossref","is-referenced-by-count":23,"title":["Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer"],"prefix":"10.1093","volume":"24","author":[{"given":"Florian J.","family":"Fintelmann","sequence":"first","affiliation":[{"name":"Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian M.","family":"Troschel","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Kuklinski","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunagh","family":"McDermott","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Petranovic","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subba R.","family":"Digumarthy","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie S.","family":"Troschel","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa C.","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida P.","family":"Hariri","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Gilman","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne O.","family":"Shepard","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lecia V.","family":"Sequist","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Piotrowska","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"key":"2021122508125902900_onco13003-bib-0001","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122508125902900_onco13003-bib-0002","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122508125902900_onco13003-bib-0003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122508125902900_onco13003-bib-0004","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","article-title":"Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer","volume":"31","author":"Gainor","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122508125902900_onco13003-bib-0005","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jtho.2016.05.008","article-title":"The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: Status in 2016","volume":"11","author":"Tan","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2021122508125902900_onco13003-bib-0006","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508125902900_onco13003-bib-0007","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508125902900_onco13003-bib-0008","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1097\/01.RVI.0000094584.83406.3e","article-title":"Society of Interventional Radiology clinical practice guidelines","volume":"14","author":"Sacks","year":"2003","journal-title":"J Vasc Interv Radiol"},{"key":"2021122508125902900_onco13003-bib-0009","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1148\/radiol.2462070712","article-title":"Fleischner Society: Glossary of terms for thoracic imaging","volume":"246","author":"Hansell","year":"2008","journal-title":"Radiology"},{"key":"2021122508125902900_onco13003-bib-0010","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1148\/radiol.12112613","article-title":"Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: Adequacy and complications","volume":"265","author":"Yoon","year":"2012","journal-title":"Radiology"},{"key":"2021122508125902900_onco13003-bib-0011","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00330-017-5006-6","article-title":"Repeat biopsy of patients with acquired resistance to EGFR TKIs: Implications of biopsy-related factors on T790M mutation detection","volume":"28","author":"Kim","year":"2018","journal-title":"Eur Radiol"},{"key":"2021122508125902900_onco13003-bib-0012","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1148\/radiology.218.2.r01fe33491","article-title":"Pneumothorax rate at lung biopsy: Are dwell time and angle of pleural puncture contributing factors?","volume":"218","author":"Ko","year":"2001","journal-title":"Radiology"},{"key":"2021122508125902900_onco13003-bib-0013","doi-asserted-by":"crossref","first-page":"W511","DOI":"10.2214\/AJR.10.4657","article-title":"CT-guided percutaneous needle biopsy of the chest: Preprocedural evaluation and technique","volume":"196","author":"Wu","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"2021122508125902900_onco13003-bib-0014","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021122508125902900_onco13003-bib-0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lungcan.2014.08.016","article-title":"Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)","volume":"86","author":"Chouaid","year":"2014","journal-title":"Lung Cancer"},{"key":"2021122508125902900_onco13003-bib-0016","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/JTO.0b013e318287c91e","article-title":"Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial","volume":"8","author":"Tam","year":"2013","journal-title":"J Thorac Oncol"},{"key":"2021122508125902900_onco13003-bib-0017","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000324997","article-title":"Efficacy of on-site specimen adequacy evaluation of image-guided fine and core needle biopsies","volume":"54","author":"Azabdaftari","year":"2010","journal-title":"Acta Cytol"},{"key":"2021122508125902900_onco13003-bib-0018","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cncy.20151","article-title":"EGFR and KRAS mutations in lung carcinoma: Molecular testing by using cytology specimens","volume":"119","author":"Billah","year":"2011","journal-title":"Cancer Cytopathol"},{"key":"2021122508125902900_onco13003-bib-0019","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.lungcan.2015.10.004","article-title":"EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291","volume":"90","author":"Thress","year":"2015","journal-title":"Lung Cancer"},{"key":"2021122508125902900_onco13003-bib-0020","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"2021122508125902900_onco13003-bib-0021","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov"},{"key":"2021122508125902900_onco13003-bib-0022","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: Clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122508125902900_onco13003-bib-0023","article-title":"Heterogeneity and coexistence of T790M and T790 wild-type resistant subclones drive mixed response to third-generation epidermal growth factor receptor inhibitors in lung cancer","volume":"2018","author":"Piotrowska","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2021122508125902900_onco13003-bib-0024","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21037\/tlcr.2017.01.01","article-title":"Comparison between endobronchial ultrasound-guided transbronchial biopsy and CT-guided transthoracic lung biopsy for the diagnosis of peripheral lung cancer: A systematic review and meta-analysis","volume":"6","author":"Zhan","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"2021122508125902900_onco13003-bib-0025","doi-asserted-by":"crossref","DOI":"10.4238\/gmr.15027001","article-title":"Comparison of EGFR mutation rates in lung adenocarcinoma tissue and pleural effusion samples","volume":"15","author":"Guan","year":"2016","journal-title":"Genet Mol Res"},{"key":"2021122508125902900_onco13003-bib-0026","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cncy.21464","article-title":"Lung cancer adrenal gland metastasis: Optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing","volume":"122","author":"Gleeson","year":"2014","journal-title":"Cancer Cytopathol"},{"key":"2021122508125902900_onco13003-bib-0027","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJM200102153440706","article-title":"Liver biopsy","volume":"344","author":"Bravo","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122508125902900_onco13003-bib-0028","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/gut.36.3.437","article-title":"Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: An audit by the British Society of Gastroenterology and the Royal College of Physicians of London","volume":"36","author":"Gilmore","year":"1995","journal-title":"Gut"},{"key":"2021122508125902900_onco13003-bib-0029","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.21873\/anticanres.12632","article-title":"Feasibility and safety of CT-guided intrathoracic and bone re-biopsy for non-small cell lung cancer","volume":"38","author":"Matsumoto","year":"2018","journal-title":"Anticancer Res"},{"key":"2021122508125902900_onco13003-bib-0030","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.anndiagpath.2013.02.001","article-title":"Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies","volume":"17","author":"Singh","year":"2013","journal-title":"Ann Diagn Pathol"},{"key":"2021122508125902900_onco13003-bib-0031","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00330-016-4357-8","article-title":"Complication rates of CT-guided transthoracic lung biopsy: Meta-analysis","volume":"27","author":"Heerink","year":"2017","journal-title":"Eur Radiol"},{"key":"2021122508125902900_onco13003-bib-0032","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1148\/radiology.181.2.1924776","article-title":"Effect of patient positioning after needle aspiration lung biopsy","volume":"181","author":"Moore","year":"1991","journal-title":"Radiology"},{"key":"2021122508125902900_onco13003-bib-0033","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1148\/radiol.11103506","article-title":"Rapid needle-out patient-rollover time after percutaneous CT-guided transthoracic biopsy of lung nodules: Effect on pneumothorax rate","volume":"262","author":"O'Neill","year":"2012","journal-title":"Radiology"},{"key":"2021122508125902900_onco13003-bib-0034","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1148\/radiol.2291020499","article-title":"CT-guided transthoracic needle aspiration biopsy of pulmonary nodules: Needle size and pneumothorax rate","volume":"229","author":"Geraghty","year":"2003","journal-title":"Radiology"},{"key":"2021122508125902900_onco13003-bib-0035","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1148\/radiol.2016132230","article-title":"Genomic adequacy from solid tumor core needle biopsies of ex vivo tissue and in vivo lung","volume":"282","author":"Jamshidi","year":"2017","journal-title":"Radiology"},{"key":"2021122508125902900_onco13003-bib-0036","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.lungcan.2009.04.007","article-title":"Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle","volume":"67","author":"Cheung","year":"2010","journal-title":"Lung Cancer"},{"key":"2021122508125902900_onco13003-bib-0037","article-title":"Coaxial technique-promoted diagnostic accuracy of CT-guided percutaneous cutting needle biopsy for small and deep lung lesions","volume":"13","author":"Zhang","year":"2018","journal-title":"PLoS One"},{"key":"2021122508125902900_onco13003-bib-0038","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1378\/chest.09-0370","article-title":"CT fluoroscopy-guided biopsy of 1,000 pulmonary lesions performed with 20-gauge coaxial cutting needles: Diagnostic yield and risk factors for diagnostic failure","volume":"136","author":"Hiraki","year":"2009","journal-title":"Chest"},{"key":"2021122508125902900_onco13003-bib-0039","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/JTO.0b013e3181f1c8de","article-title":"Consensus for EGFR mutation testing in non-small cell lung cancer: Results from a European workshop","volume":"5","author":"Pirker","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2021122508125902900_onco13003-bib-0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1148\/radiol.2015150381","article-title":"Frequency and severity of pulmonary hemorrhage in patients undergoing percutaneous CT-guided transthoracic lung biopsy: Single-institution experience of 1175 cases","volume":"279","author":"Tai","year":"2016","journal-title":"Radiology"},{"key":"2021122508125902900_onco13003-bib-0041","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jvir.2016.12.1217","article-title":"Pulmonary intraparenchymal blood patching decreases the rate of pneumothorax-related complications following percutaneous CT-guided needle biopsy","volume":"28","author":"Graffy","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"2021122508125902900_onco13003-bib-0042","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/01.RVI.0000124951.24134.50","article-title":"Factors associated with pneumothorax and pneumothorax requiring treatment after percutaneous lung biopsy in 443 consecutive patients","volume":"15","author":"Covey","year":"2004","journal-title":"J Vasc Interv Radiol"},{"key":"2021122508125902900_onco13003-bib-0043","doi-asserted-by":"crossref","first-page":"W404","DOI":"10.2214\/AJR.17.18691","article-title":"Prevention of air embolism during transthoracic biopsy of the lung","volume":"209","author":"Fintelmann","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"2021122508125902900_onco13003-bib-0044","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejrad.2008.01.006","article-title":"CT-guided cutting needle lung biopsy using modified coaxial technique: Factors effecting risk of complications","volume":"70","author":"Yildirim","year":"2009","journal-title":"Eur J Radiol"},{"key":"2021122508125902900_onco13003-bib-0045","doi-asserted-by":"crossref","first-page":"W678","DOI":"10.2214\/AJR.10.4659","article-title":"Complications of CT-guided percutaneous needle biopsy of the chest: Prevention and management","volume":"196","author":"Wu","year":"2011","journal-title":"AJR Am J Roentgenol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0158","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0158","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/12\/1570\/41919339\/oncolo_24_12_1570.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/12\/1570\/41919339\/oncolo_24_12_1570.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:13:51Z","timestamp":1640420031000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/12\/1570\/6439460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":45,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,5,31]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0158","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12,1]]},"published":{"date-parts":[[2019,5,31]]}}}